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https://doi.org/10.1016/j.stemcr.2020.12.018SUMMARYMutations in the photoreceptor transcription factor gene cone-rod homeobox (CRX) lead to distinct retinopathy phenotypes, including
early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Using induced pluripotent stem cells (iPSCs) from a pa-
tientwithCRX-I138fs48mutation,we established an in vitromodel ofCRX-LCA in retinal organoids that showed defective photoreceptor
maturation by histology and gene profiling, with diminished expression of visual opsins. Adeno-associated virus (AAV)-mediated CRX
gene augmentation therapy partially restored photoreceptor phenotype and expression of phototransduction-related genes as deter-
mined by single-cell RNA-sequencing. Retinal organoids derived from iPSCs of a second dominant CRX-LCA patient carrying K88N
mutation revealed the loss of opsin expression as a common phenotype, which was alleviated by AAV-mediated augmentation of
CRX. Our studies provide a proof-of-concept for developing gene therapy of dominant CRX-LCA and other CRX retinopathies.INTRODUCTION
Leber congenital amaurosis (LCA) constitutes a group of
rare early-onset retinal dystrophies with severe clinical
manifestations, resulting in vision loss during infancy
(den Hollander et al., 2008). LCA is genetically heteroge-
neous with mutations identified in at least 25 genes; a
vast majority of these are crucial for photoreceptor devel-
opment and/or function (Kumaran et al., 2017). Most pa-
tients with LCA exhibit autosomal recessive inheritance.
Mouse models have been valuable for elucidating disease
etiology (Veleri et al., 2015) and for preclinical therapy
development, leading to the first U.S. Food and Drug
Administration-approved adeno-associated virus (AAV)-
based gene therapy of recessive LCA caused by RPE65 mu-
tations (Apte, 2018). However, it is widely recognized that
available animal models do not fully capture complexities
of human disease, slowing further clinical translation. No
treatment currently exists for other, especially dominant,
forms of LCA.
Cone-rod homeobox protein CRX is essential for devel-
opment of photoreceptors in the retina (Furukawa et al.,
1999). CRX controls expression of most rod and cone
photoreceptor genes through its interaction with bZIP
transcription factor NRL (Mitton et al., 2000) and/or an
intricate network of regulatory proteins (Hennig et al.,
2008). Heterozygous mutations in CRX cause early-onset252 Stem Cell Reports j Vol. 16 j 252–263 j February 9, 2021 j
This is an open access article under the CC BY license (http://creativecommoretinal dystrophies with extensive phenotypic heterogene-
ity, with rare reports of biallelic variants in LCA (Huang
et al., 2012; Hull et al., 2014; Ibrahim et al., 2018; Rivolta
et al., 2001; Swaroop et al., 1999). Notably, a majority of
reported dominant LCA can be attributed to CRX. Dis-
ease-causing CRX mutations can either reduce the tran-
scriptional activity or impart a gain of function effect
(Tran et al., 2014). Studies in animal models revealed a se-
vere phenotype associated with dominant frameshift mu-
tations inCrx comparedwith loss-of-function alleles (Roger
et al., 2014; Tran et al., 2014).
We previously described clinical presentations of two pe-
diatric patients carrying c.G264T (p.K88N)- or c.413delT
(p.I138fs48) dominant CRX mutations manifested as
LCA, with a complete loss of light-evoked responses in
electroretinogram recordings (Nichols et al., 2010). Impor-
tantly, retinal imaging revealed preservation of outer
nuclear layer, suggesting presence of viable but nonfunc-
tional photoreceptors, which could be potential targets
for gene therapy. Molecular analysis of mutant alleles
demonstrated differential interaction with NRL in vitro,
suggesting interference with gene regulation in rod photo-
receptors (Nichols et al., 2010). Although animal models
phenocopy human CRX retinopathies (Roger et al., 2014;
Tran et al., 2014) and can provide proof-of-concept for
treatment (Watanabe et al., 2013), there are significant
differences in development, cell-type composition, andns.org/licenses/by/4.0/).
molecular profiles of human retina (Hoshino et al., 2017).
Therefore, we decided to take advantage of patient-
derived induced pluripotent stem cells (iPSCs) to create a
human model for developing therapeutic paradigms for
CRX-LCA.
Directed differentiation of iPSCs into three-dimensional
(3D) retinal organoids has enabled themodeling of retinop-
athies in patient-specific genetic background (Kruczek and
Swaroop, 2020). Next generation sequencing technologies
have provided a detailed comparison of developing retinal
organoids with human retina (Collin et al., 2019; Cowan
et al., 2020; Hoshino et al., 2017; Kaya et al., 2019; Kim
et al., 2019) andpermit evaluationofmajor retinal cell types
in a disease context. In this study, we established a retinal
organoid model of CRX-LCA from patient-derived iPSCs
and demonstrate perturbation in molecular phenotype of
photoreceptors, including diminished expression of visual
opsins, in concordancewith clinically observed loss of light
responses.We also show partial restoration of both rod and
cone gene expression by delivering correct CRX transgene
driven by a human CRX promoter via an AAV vector. Our
studies provide a path forward for treatment of dominant
CRX-LCA by gene augmentation.RESULTS
Skin biopsies of two LCA patients carrying dominant
c.G264T (p.K88N) or c.413delT (p.I138fs48) mutation in
theCRX gene (Figure 1A), aswell as unaffected familial con-
trols (Table S1), were used to derive iPSC lines, which
demonstrated normal karyotype and typical features of
stem cells (Figure S1A, S1B, S5A, and S5B; Table S2). Retinal
organoids were differentiated using a previously published
protocol (Kaya et al., 2019; Zhong et al., 2014) (Figure 1B).
Pairwise comparisons of organoids derived from each pa-
tient to respective healthy familial control were performed
in all presented data. Both patient and control cell lines
formed morphologically similar retinal neural epithelia
(Figures S1C and S5C).
Given that a frameshift mutation showed a particularly
severe retinal phenotype in CrxRip mouse model (Roger
et al., 2014), we first examined the organoids derived
from c.413delT(p.I138fs48) iPSCs. Retinal organoids
exhibit three stereotypical stages of differentiation (Ca-
powski et al., 2019; Kaya et al., 2019) corresponding to
developmental epochs in human fetal retina (Hoshino
et al., 2017). At stage 1, neuroepithelia of control and pa-
tient organoids were indistinguishable (Figures S1C–S1E).
During stage 2, CRX-expressing photoreceptors aligned at
the apical side of neural retina in both control and patient
organoids (Figure 1C) and stained positive for early photo-
receptormarker, Recoverin (Figure 1D). Immunoblotting ofday 90 organoid protein extracts revealed a truncated CRX
protein (referred as I138fs) in patient samples (Figure 1E).
Quantification of the protein bands indicated higher levels
of total CRX in patient samples with a significant propor-
tion contributed by the mutant allele (Figure 1F). The
phenotypic distinction between the control and patient or-
ganoids was evident at stage 3, when photoreceptors began
to form outer segment-like structures visible as an apical
‘‘brush’’ in light microscopy. While clearly detectable in
control organoids, formation of these structures was abro-
gated in CRX-I138fs patient organoids (Figure 2A; details
of sampling size used for quantifications and description
of statistical analyses are provided in methods and figure
legends). As early as day 125, control organoids showed
patches of developing rods as revealed by immunostaining
of the rod visual pigment Rhodopsin, a transcriptional
target of CRX. However, Rhodopsin staining was virtually
absent in CRX-I138fs organoids (Figure 2B). Similarly,
cone photoreceptor opsins displayed altered expression. S
Opsin immunostaining was delayed compared with the
control (Figures S2A–S2F), whereas the number of L/M
Opsin + cones was substantially reduced (Figure 2C). 3D
renderings of organoids at day 200 confirmed the dimin-
ished opsin staining (Figure 2D, Videos S1 and S2). Another
outer segment component, Peripherin2, was also dramati-
cally reduced in CRX-I138fs organoids (Figure 2E). In
contrast, developing ribbon synapses appeared unaffected
(Figures S2G and S2H). Transcriptome analysis at key stages
of organoid differentiation, days 90, 125, 150, and 200,
identified differential expression of multiple transcripts
associated with photoreceptor function (Figure 2F), consis-
tent with the established role of CRX (Furukawa et al.,
1999; Hennig et al., 2008). Rod and L/M cone opsins
(RHO, OPN1MW) were the most significantly diminished
transcripts in CRX-I138fs organoids (Figure 2F), in accor-
dance with immunostaining results (Figures 2B and 2C).
Thus, histological and transcriptome analyses of retinal or-
ganoids showed aberrant photoreceptor development due
to the I138fs mutation in CRX.
Next, we asked whether gene augmentation with normal
CRX might alleviate the disease phenotype by competing
with the mutant isoform. First, we tested transduction
with two commonly used AAV capsid serotypes AAV2
and AAV8 with cytomegalovirus (CMV) promoter driving
a GFP reporter. AAV2 capsid showed much higher propor-
tion of cells expressing both GFP and CRX in organoids
at day 150, 10 days post vector addition at day 140 (Fig-
ure 3A). We then tested human CRX promoter sequences
for driving transcription in retinal cells that normally
express the CRX gene. Three promoter fragments were
combined to generate a shorter composite promoter
(see Table S5), whichwas placed upstream of GFP and pack-
aged into AAV2 capsid (Figure 3B). As compared withStem Cell Reports j Vol. 16 j 252–263 j February 9, 2021 253
Figure 1. Differentiation of Photoreceptors in CRX-I138fs Retinal Organoids
(A) Schematic representation of CRX protein, showing domain structure and the positions of dominant pathological mutations in the study
patients. Number of amino acid residue is indicated over the bar. N and C indicate amino- and carboxyl-terminal of the CRX protein.
(B) An overview of the retinal organoid differentiation protocol.
(C) CRX expression in developing photoreceptors at day 90. CRX antibody labeled apically aligning developing photoreceptors in both
control and patient organoids. Scale bar, 50 mm. Note a more diffuse pattern in the patient sample. Nuclei were stained with DAPI (40,6-
diamidino-2-phenylindole).
(D) Developing photoreceptors of both genotypes also express the marker protein Recoverin. Scale bar, 20 mm.
(E) Immunoblot analysis of organoid protein extracts at day 90. Molecular mass markers (kDa) are indicated on the left. Protein samples
from control and patient stem cell-derived organoids (n = 3 biological replicates containing three organoids each) were run in separate
lanes. Tubulin was used as a loading control. A smaller molecular weight band, which corresponds to the mutant CRX-I138fs48 isoform, is
evident in the patient samples.
(F) Densitometry quantification of CRX protein bands normalized to the Tubulin loading control. Total CRX protein is significantly more
abundant in CRX-I138fs patient samples. Mean ± SD plotted, *p < 0.05, ***p < 0.001, one-way ANOVA.
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Figure 2. Impaired Photoreceptor Maturation in CRX-LCA Retinal Organoids
(A) Brightfield images of apical aspect of organoid neural retina. Scale bar, 400 mm. Note loss of brush-like outer segment (OS) structures
in patient (arrowheads).
(B) Rhodopsin (RHO) immunostaining at day 125 and fluorescence intensity quantification. Nuclei were stained with DAPI (40,6-
diamidino-2-phenylindole). Scale bar, 20 mm.
(C) L/M Opsin immunostaining with quantification of positive cells. Scale bar, 20 mm.
(D) Representative whole-mount confocal images of organoids at day 200 immunostained for RHO, L/M Opsin, and Visual System
Homeobox 2 (VSX2). Scale bar, 160 mm.
(E) Peripherin2 (PRPH2) staining and puncta quantification. Scale bar, 10 mm.
(F) Heatmap comparing expression of genes (bulk RNA-seq) across organoid development (days 90, 125, 150, and 200). Values are shown
as log2(CPM+1). TFs, transcription factors; OS, outer segment. Number of organoids per genotype analyzed for quantifications: (A) control
n = 10, patient n = 10; (B) control n = 8, patient n = 5; (C) n = 5 control, n = 3 patient; (E) control n = 3, patient n = 3. Values represent mean
± SD with individual data points plotted (three sections per organoid). Statistical significance was determined by Student’s t test; p values
indicated.transduction with ubiquitously expressed CMV promoter,
CRX promoter-driven GFP signal localized to a distinct api-
cal lamina corresponding to the photoreceptor layer in
both control andCRX-I138fs patient organoids (Figure 3B).
The final therapeutic construct contained this CRX
composite promoter driving human CRX expression (Fig-
ure 3C). This AAV-CRX vector was added to patient organo-
ids at day 120, and the samples were analyzed at days 150
and 180. Transduction with the vector increased CRXmRNA and protein in treated organoids (Figures S3A–
S3D). Rhodopsin and L/M Opsin expression were used as
surrogates for treatment, given their near absence in
patient organoids. Retinal organoids transduced with
131011 vector genomes (vg) began to show rescue of
Rhodopsin expression by day 150 (Figures S3E and S3F),
which became more widespread by day 180 (Figure 3D).
Quantification of Rhodopsin immunolabeling intensities
confirmed higher fluorescence compared with untreatedStem Cell Reports j Vol. 16 j 252–263 j February 9, 2021 255
Figure 3. AAV-Delivered Gene Augmentation for CRX-LCA Caused by I138fs Mutation
(A) Transduction of CRX-expressing cells by AAV2 and AAV8 serotypes. Quantification of percent of AAV-delivered GFP reporter in CRX-
positive cells on control organoid cryosections. Scale bar, 20 mm. For both serotypes, n = 4 organoids, three sections each averaged; mean
± SD, statistical significance by Student’s t test, p value indicated.
(B) Promoter testing in retinal organoids. Comparison of GFP reporter expression driven by CMV or CRX promoters in day 150 control
organoids (left; scale bar, 20 mm). Note broad expression using CMV as compared with localization primarily to outer organoid layer with
CRX promoter. GFP expression driven by CRX promoter in CRX-I138fs48 patient organoids at day 200 (right). Nuclei were stained with DAPI
(40,6-diamidino-2-phenylindole). Scale bar, 200 mm.
(C) Schematic representation of the therapeutic AAV vector design and testing in retinal organoids.
(D and E) Rhodopsin (D) and Cone L/M Opsin (E) staining in healthy control, and untreated and AAV-treated patient retinal organoids at
day 180. Two doses of AAV-CRX vector were tested (131011 and 331011 vg per organoid). Scale bar, 20 mm. Efficiency of treatment was
evaluated with quantification of Rhodopsin expression rescue and percentage of L/M Opsin + cones. Number of organoids analyzed for
quantifications: (D) control n = 4, untreated and AAV-treated n = 3 each dose; (E) control and untreated n = 6; AAV-treated n = 5 each dose;
three sections each. Values represent mean ± SD with individual data points plotted. Statistical significance was determined by one-way
ANOVA; p values indicated.
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Figure 4. Long-Term Effects of AAV-CRX Gene Augmentation in CRX-I138fs Retinal Organoids
Retinal organoids were transduced at day 120 with AAV-CRX vector at 131011 vg per organoid and examined 180 days later, at day 300 in
culture. Immunostaining for (A) Rhodopsin, (B) L/M Opsin, (C) cleaved Caspase3. Nuclei were counterstained with DAPI. Note the
continued presence of cells with rescued expression of opsins. Prolonged CRX expression does not appear to induce apoptotic cell death in
the photoreceptor layer, where cleaved Caspase3 staining is absent (C, left), in contrast to the core region of the organoid showing
extensive apoptosis in extended culture (C, right). Scale bar in all images, 20 mm.patient iPSC-derived organoids with both 131011 vg and
331011 vg doses and was almost half of signal intensity
measured for the healthy control (Figure 3D). Fluorescence
intensity levels were similar at both vector doses, suggest-
ing that 131011 vg per organoid is sufficient for substantial
rescue of Rhodopsin expression. Treatment also partially
restored L/M Opsin expression (Figures 3E, S3G, and
S3H). Rescue effect persisted at least for 6 months after
treatment (day 300) with both Rhodopsin and L/M
Opsin-positive cells still detectable (Figures 4A and 4B).
Long-term expression of CRX did not lead to activation
of the apoptotic marker Caspase3 in AAV-treated organoid
neural retina (Figure 4C).
To decipher and validate the impact of CRX-I138fs muta-
tion on specific cell types within retinal organoids, we per-
formed single-cell RNA-sequencing (scRNA-seq) using 10x
Genomics platform. Control, untreated CRX-I138fs and
AAV-treated organoids were dissociated using a papain-
based method (Fadl et al., 2020) at day 200 yielding
40,712 single-cell transcriptional profiles. Data processing
using Seurat package identified cell clusters, which were as-
signed to known retinal cell types and visualized using
UMAP dimension reduction (Figure 5A and S4A–S4C). In
this representation, major retinal cell classes (apart from
ganglion cells) emerge from centrally located undifferenti-
ated cells (Figure 5A). Cell-type distribution was similaracross the three sample origins (Figures 5A and S4B). Rods
and cones formed well-defined differentiation trajectories
in this manifold and were identified by expression of
both common (CRX, RCVRN) and subtype-specificmarkers
(rod: GNGT1, GNAT1; cone: ARR3, PDE6H; Figures 5B,
S4D,and S4E). As predicted, CRX transcripts increased in
photoreceptors after AAV-CRX transduction (Figure 5C).
Rod and cone expression profiles could be clearly separated
based on control or patient sample origin, whereas AAV-
treated cells occupied the space in between (Figures 5D,
5E, 5G, and 5H). This shift was particularly evident by plot-
ting the origin of most cells across hexagonal bins (Figures
5E and 5H). ScRNA-seq detected partially rescued expres-
sion of opsins following AAV treatment (RHO, OPN1MW3,
Figures 5F and 5I; OPN1MW3 was the most significantly
dysregulated of three medium wavelength opsin genes
OPN1MW1-3), as well as of other rod- and cone-specific
transcripts (Figures S4D and S4E; for each gene adjusted p
value <0.05, nonparametric Wilcoxon rank-sum test with
Bonferroni correction; minimum percent expressed =
10% cells, minimum log fold change = 0.25). CABP4, a
retinal disease gene and direct transcriptional target of
CRX (Assawachananont et al., 2018) showed a similar
trend (Figures S4F and S4G). Thus, single-cell analysis
confirmed treatment effect of AAV-mediated overexpres-
sion of normal CRX.Stem Cell Reports j Vol. 16 j 252–263 j February 9, 2021 257
(legend on next page)
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To determine whether the observed phenotypes and
rescue were mutation-specific or could be generalized to
other cases of dominantCRX-LCA, we examined organoids
with the CRX K88N mutation. As for the frameshift muta-
tion, no differences in morphology and expression of key
retinal markers were evident at stage 1 or 2 of organoid dif-
ferentiation (Figures S5C–S5E). However, outer segment-
like structures were less developed at stage 3 in patient
iPSC-derived organoids compared with the control (Figures
6A and 6B). Immunostaining showed the presence of CRX
and Recoverin, but severely diminished Rhodopsin and
L/M Opsin staining in CRX-K88N organoids (Figure 6C).
Transcriptome analyses at days 120 and 200 revealed de-
layed upregulation of many photoreceptor-specific genes
(Figure 6D) and confirmed the loss of Rhodopsin and L/M
Opsin expression (RHO, OPN1MW2; Figure 6D). Treatment
of CRX-K88N organoids with AAV-CRX vector increased
CRX levels (Figure S6A), partially rescued Rhodopsin and
L/M Opsin expression (Figures 6E–6G) and reduced
abnormal S Opsin levels (Figure S6B), with a modest induc-
tion of rod visual arrestin and synaptic proteins (Fig-
ure S6B). Thus, CRX-K88N organoids showed a similar
phenotype to CRX-I138fs, and AAV gene therapy was
able to restore expression of CRX target genes.DISCUSSION
Dominant diseases represent a considerable challenge for
developing gene therapy because of the presence of a
mutant allele that interferes with normal function (Ahmed
et al., 2019; Collin et al., 2019). Overexpression of a normal
copy of Rhodopsin or VSX2 has been shown to partially
correct defects in mouse or retinal organoid models of
respective dominant disease (Mao et al., 2011; Phillips
et al., 2014). We previously observed reexpression of
Rhodopsin following electroporation of wild-type Crx
into the retina of a mouse model harboring a spontaneous
dominant frameshiftmutation in theCrx gene (Roger et al.,
2014). Building on that observation, we tested the hypoth-Figure 5. Altered Gene Expression Patterns and AAV Treatment Ef
Patient Retinal Organoids at day 200
(A) Top: UMAP representation of the single-cell RNA-seq dataset (n = 4
known cell-type marker genes). Bottom: UMAP plots showing the dist
each), and untreated and AAV-CRX (n = 2 biological replicates, 3 org
(B) Expression of photoreceptor cell-type- (CRX, RCVRN) and subtype
(C) Violin plot profiles of CRX expression levels in rods and cones. No
(D–I) Treatment effects in rod (D–F) and cone (G–I) photoreceptor su
cone cells by sample origin (control, blue; untreated, red; AAV-CRX, gre
(coloring each hexagon according to the origin of the majority of cell
and control sample majority areas. (F and I) Opsin transcript reads in
derived samples following treatment. Percentages of cells of each oriesis that overexpression of a correct CRX cDNA increasing
the ratio of normal tomutant protein (gene augmentation)
may rescue defects in dominant humanCRX retinopathies.
We developed retinal organoid models of dominant CRX-
LCA from patients with two different mutation types and
demonstrate the feasibility of using AAV-delivered CRX as
a therapeutic strategy. We note that patient iPSC-derived
organoids have recently been used to provide proof-of-con-
cept for AAV-mediated gene therapy of recessive X-linked
retinitis pigmentosa caused by mutations in RP2 (Lane
et al., 2020).
CRX-LCA patient organoids showed impaired matura-
tion of photoreceptors with particularly disrupted expres-
sion patterns of visual opsins. Rhodopsin and L/M cone
opsins were almost undetectable, whereas S Opsin expres-
sion was initially delayed but recovered later, consistent
with findings in animal models (Roger et al., 2014; Tran
et al., 2014). We observed increased total CRX protein
levels in organoids of the patient with I138fs mutation,
especially of the mutant isoform, whereas K88N organoids
showed reduced overall levels of CRX protein. These find-
ings suggest distinct potential downstream impacts of the
dominant alleles: (1) competition of mutant protein with
normal CRX for target binding sites, (2) prolonged occu-
pancy of mutant protein at binding sites preventing the
correct form from associating to the target DNA, and (3)
disruption of stoichiometric interactions with other retinal
transcription factors, such as NRL. The contribution of
these mechanismsmay vary depending on a specific muta-
tion, but as we demonstrate, convergent molecular pathol-
ogy such as disruption of opsin expression is evident.
We took advantage of scRNA-seq to determine disease-
associated changes in photoreceptor subtypes as well as
to evaluate treatment effect following gene therapy. We
observed clear separation of patient cones and rods from
control populations and reduced expression of cell-type-
specific genes. In rods, partial shift toward control popula-
tion with AAV treatment is associated with higher rescue of
Rhodopsin expression in a subset of transduced cells, vali-
dating histological observations. Importantly, we detectedfects in Cone and Rod Photoreceptor Subtypes of CRX-I138fs48
0,712 transcriptomes) displaying major cell types (annotated using
ribution of cells of control (n = 2 biological replicates, 4 organoids
anoids each) organoid samples.
-specific markers (rods: GNGT1, GNAT1; cones: ARR3, PDE6H).
te increased expression with AAV-CRX gene augmentation.
btypes. (D and G) UMAP plots showing the distribution of rod and
en). (E and H) Hexagonal bin plots illustrating identity of cell origin
s it covers). Note placement of AAV-CRX treatment between patient
the different samples visualizing increased expression in patient-
gin in which transcript reads were detected are indicated.
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Figure 6. Disease Phenotype and Gene Augmentation Therapy of CRX-K88N Patient Retinal Organoids
(A) Brightfield images of control and CRX-K88N patient organoids showing reduced outer segment (OS) apical ‘‘brush’’ layer (arrowheads).
(B) Quantification of the outer segment-like layer thickness; n = 6 organoids per group, three sections each; mean ± SD, p values from one-
way ANOVA.
(C) Immunostaining of organoids at day 200 for CRX, Recoverin, Rhodopsin and L/M Opsin. Note diminished Rhodopsin and L/M Opsin
staining in patient-derived organoids. Nuclei were stained with DAPI (40,6-diamidino-2-phenylindole). Scale bar, 100 mm.
(D) Heatmap comparing expression of genes (bulk RNA-seq) of day 120 and day 200 organoids. Expression of many photoreceptor-specific
transcripts is either delayed or reduced in CRX-K88N patient samples. Normalized log2(CPM+1) values plotted. TFs, transcription factors;
OS, outer segment.
(E) AAV treatment assessment by immunostaining. Immunoreactivity for both Rhodopsin and L/M Opsin is partially restored following AAV
treatment. Scale bar, 100 mm.
(legend continued on next page)
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continued rescue of Rhodopsin and L/MOpsin at 6months
posttreatmentwithout any indication of apoptosis. Further
investigations are needed to define optimal dosing as well
as time window for gene therapy. In addition, we may
require in vivo model(s) to fully evaluate the long-term
impact of augmented CRX expression. In any event, sin-
gle-cell transcriptomics offers a powerful approach to assess
treatment approaches for retinopathies.
The difference in rescue of L/M Opsin expression was
evident between patient organoids of the two genotypes,
suggesting differential interaction of mutant CRX with
binding partners in cones. While restoration of cone gene
expression was clearly evident in our study, further
enhancement is likely by selecting a more potent capsid
serotype targeting cones (Gonzalez-Cordero et al., 2018).
Treatment of cone photoreceptors is of relevance because
mutations in CRX also cause milder adult-onset cone-rod
dystrophies and macular dystrophies, which could poten-
tially benefit from gene therapy treatment described here.
In conclusion, we used retinal organoids as a platform to
examine disease mechanisms and design gene augmenta-
tion therapy for dominant CRX-LCA. We suggest that our
experimental strategy should be applicable in developing
effective treatments for rare, and even dominant, inherited
diseases of the retina and other parts of the central nervous
system.EXPERIMENTAL PROCEDURES
Retinal organoids from patient-derived iPSCs
Skin biopsies were obtained from two CRX-LCA pediatric patients
and respective healthy parental controls with informed consent
(Table S1). Dermal fibroblasts were reprogrammed to generate
iPSCs using a Sendai virus-based approach. Resulting iPSC lines
were of normal karyotype and free of mycoplasma contamination
(Table S2). iPSCs were differentiated following an established pro-
tocol (Kaya et al., 2019) with a minor modification of culturing
dissected retinal organoids individually in a 96-well plate format
(Table S3). Histology was performed as described in (Shimada
et al., 2017), a list of all primary antibodies used for immunofluo-
rescent staining is provided in Table S4. Images were obtained on
Zeiss 700 confocal microscope.
Next generation sequencing
RNA was isolated from three pooled frozen organoids per sample
using the QIAGEN RNeasy Kit according to manufacturer’s
manual. RNA quality was assessed using the Agilent 2100 Bio-
analyzer (Agilent Technologies). Samples (with RNA integrity
number >7) were used for library generation using the TruSeq(F) Quantification of Rhodopsin fluorescence intensity in AAV-treated
n = 6 organoids; three sections each; mean ± SD, p values from one-
(G) Quantification of the percentage of L/M Opsin + cones in AAV-treat
n = 8 organoids; three sections each; mean ± SD, p values from one-Library Preparation Kit (Illumina Inc). Sequencing and bio-
informatic analysis were performed as described (Kaya et al.,
2019).
For single-cell RNA-seq, organoids were dissociated following a
papain-based method and subjected to single-cell isolation and
sequencing as described (Fadl et al., 2020). Processing and analysis
of single-cell transcriptomes using Seurat package is detailed in
Supplemental information.
Cloning of a composite human CRX promoter
Three fragments from the human CRX 50 untranslated region
(NCBI: NG_008605.1) were amplified from human genomic
DNA and ligated to produce a 631 base pair promoter sequence
(Table S5). In this promoter, 189 nucleotides correspond to posi-
tions 3,085–3,274, 69 correspond to 3,323–3,392, and 361 corre-
spond to 4,808–5,169 of the reference. This promoter element
contains first exon of the human CRX gene (nucleotides 4,999–
5,169).
Statistical analysis
At least three independently cultured organoids (individual wells
of a 96-well plate) were used for quantification. Three differentia-
tion batches were analyzed to verify disease phenotypes. In histo-
logical analyses, data from three sections were averaged to account
for regional variation within individual organoids. With respect to
next generation sequencing and single-cell sequencing, three orga-
noids were pooled to obtain one sample. GraphPad Prism version
8.0 software was used to plot data and perform statistical analysis.
For two group comparisons two-tailed Student’s t test was used. For
multiple groups, one-way ANOVA analysis was used with either
Dunnett’s or Tukey’s post hoc tests.Quantitative data are presented
as means ± standard deviation (SD). Exact p values are reported in
the figures, and p values of <0.05 were considered statistically
significant.
Study approval
Skin biopsies were obtained from the patients and unaffected
familymembers at theNational Eye InstituteClinicalCenter under
an institutional review board-approved protocol #15-EI-0128,
NCT01432847.
Detailed description of all experimental methods is provided in
Supplemental information.
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper
is GEO: GSE153101.
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10.1016/j.stemcr.2020.12.018.retinal organoids. Control n = 6, untreated n = 5, and AAV-treated
way ANOVA.
ed retinal organoids. Control n = 7, untreated n = 7, and AAV-treated
way ANOVA.
Stem Cell Reports j Vol. 16 j 252–263 j February 9, 2021 261
AUTHOR CONTRIBUTIONS
Conceptualization, A. Swaroop, K.K.; Methodology, Investigation,
Validation and Analysis, K.K., Z.Q., L.C., C.J.C., S.H., M.S., A.Sa-
manta; Data curation and analysis, and Visualization, J.G., B.R.F.,
Z.B.; Resources, L.G., S.H., Z.W., B.P.B.; Writing – Original draft,
K.K., A. Swaroop; Writing – Review & Editing, all authors; Project
administration and supervision, Funding acquisition, A. Swaroop.
CONFLICTS OF INTEREST
K.K., S.H., Z.W., and A.S. are inventors on a patent application
‘‘Gene therapy for treatment of CRX-associated retinopathies,’’
submitted by the National Eye Institute. Z.W. is now an employee
of PTC Therapeutics. Other authors declare no conflict of interest.
ACKNOWLEDGMENTS
We are grateful to the patients and their families for tissue dona-
tions, which enabled this study. We thank Jeanette Beers at the
NIH/National Heart, Lung, and Blood Institute iPS and Genome
Engineering Core Facility for generating iPSC lines, Sandra Burkett
at the Molecular Cytogenetics Core Facility, National Cancer Insti-
tute Center for Cancer Research for karyotyping, and Milton A.
English and Charles Drinnan for fibroblast cell line generation
and stem cell maintenance. This research was supported by the
Intramural Research Programs of the National Eye Institute
(ZIAEY000450 and ZIAEY000546 to A. Swaroop) and, in part, by
the National Institute of Allergy and Infectious Diseases, National
Institutes of Health.We are grateful to Opsomai Foundation (Italy)
for a generous donation, which partly funded this work. This work
used the high-performance computational capabilities of the NIH
Biowulf Linux cluster (http://hpc.nih.gov).
Received: August 13, 2020
Revised: December 27, 2020
Accepted: December 28, 2020
Published: January 28, 2021REFERENCES
Ahmed, C.M., Dwyer, B.T., Romashko, A., Van Adestine, S., Park,
E.H., Lou, Z., Welty, D., Josiah, S., Savinainen, A., Zhang, B.,
et al. (2019). SRD005825 acts as a pharmacologic chaperone of
opsin and promotes survival of photoreceptors in an animalmodel
of autosomal dominant retinitis pigmentosa. Transl. Vis. Sci. Tech-
nol. 8, 30.
Apte, R.S. (2018). Gene therapy for retinal degeneration. Cell
173, 5.
Assawachananont, J., Kim, S.Y., Kaya, K.D., Fariss, R., Roger, J.E.,
and Swaroop, A. (2018). Cone-rod homeobox CRX controls pre-
synaptic active zone formation in photoreceptors of mammalian
retina. Hum. Mol. Genet. 27, 3555–3567.
Capowski, E.E., Samimi, K., Mayerl, S.J., Phillips, M.J., Pinilla, I.,
Howden, S.E., Saha, J., Jansen, A.D., Edwards, K.L., Jager, L.D.,
et al. (2019). Reproducibility and staging of 3D human retinal or-
ganoids across multiple pluripotent stem cell lines. Development
146, dev171686.262 Stem Cell Reports j Vol. 16 j 252–263 j February 9, 2021Collin, J., Queen, R., Zerti, D., Dorgau, B., Hussain, R., Coxhead, J.,
Cockell, S., and Lako,M. (2019). Deconstructing retinal organoids:
single cell RNA-seq reveals the cellular components of human
pluripotent stem cell-derived retina. Stem Cells 37, 593–598.
Cowan, C.S., Renner, M., De Gennaro, M., Gross-Scherf, B., Gold-
blum, D., Hou, Y., Munz, M., Rodrigues, T.M., Krol, J., Szikra, T.,
et al. (2020). Cell types of the human retina and its organoids at
single-cell resolution. Cell 182, 1623–1640.e34.
den Hollander, A.I., Roepman, R., Koenekoop, R.K., and Cremers,
F.P. (2008). Leber congenital amaurosis: genes, proteins and disease
mechanisms. Prog. Retin. Eye Res. 27, 391–419.
Fadl, B.R., Brodie, S.A.,Malasky,M., Boland, J.F., Kelly,M.C., Kelley,
M.W., Boger, E., Fariss, R., Swaroop, A., andCampello, L. (2020). An
optimized protocol for retina single-cell RNA sequencing.Mol. Vis.
26, 705–717.
Furukawa, T., Morrow, E.M., Li, T., Davis, F.C., and Cepko, C.L.
(1999). Retinopathy and attenuated circadian entrainment in
Crx-deficient mice. Nat. Genet. 23, 466–470.
Gonzalez-Cordero, A., Goh, D., Kruczek, K., Naeem, A., Fernando,
M., Kleine Holthaus, S.M., Takaaki, M., Blackford, S.J.I., Kloc, M.,
Agundez, L., et al. (2018). Assessment of AAV vector tropisms for
mouse and human pluripotent stem cell-derived rpe and photore-
ceptor cells. Hum. Gene Ther. 29, 1124–1139.
Hennig, A.K., Peng, G.H., and Chen, S. (2008). Regulation of
photoreceptor gene expression byCrx-associated transcription fac-
tor network. Brain Res. 1192, 114–133.
Hoshino, A., Ratnapriya, R., Brooks, M.J., Chaitankar, V., Wilken,
M.S., Zhang, C., Starostik, M.R., Gieser, L., La Torre, A., Nishio,
M., et al. (2017). Molecular anatomy of the developing human
retina. Dev. Cell 43, 763–779.
Huang, L., Xiao, X., Li, S., Jia, X., Wang, P., Guo, X., and Zhang, Q.
(2012). CRX variants in cone-rod dystrophy and mutation over-
view. Biochem. Biophys. Res. Commun. 426, 498–503.
Hull, S., Arno, G., Plagnol, V., Chamney, S., Russell-Eggitt, I.,
Thompson, D., Ramsden, S.C., Black, G.C., Robson, A., Holder,
G.E., et al. (2014). The phenotypic variability of retinal dystrophies
associated with mutations in CRX, with report of a novel macular
dystrophy phenotype. Invest. Ophthalmol. Vis. Sci. 55, 6934–
6944.
Ibrahim, M.T., Alarcon-Martinez, T., Lopez, I., Fajardo, N., Chiang,
J., and Koenekoop, R.K. (2018). A complete, homozygous CRX
deletion causing nullizygosity is a new genetic mechanism for
Leber congenital amaurosis. Sci. Rep. 8, 5034.
Kaya, K.D., Chen, H.Y., Brooks, M.J., Kelley, R.A., Shimada, H., Na-
gashima, K., de Val, N., Drinnan, C.T., Gieser, L., Kruczek, K., et al.
(2019). Transcriptome-based molecular staging of human stem
cell-derived retinal organoids uncovers accelerated photoreceptor
differentiation by 9-cis retinal. Mol. Vis. 25, 663–678.
Kim, S., Lowe, A., Dharmat, R., Lee, S., Owen, L.A., Wang, J., Sha-
koor, A., Li, Y., Morgan, D.J., Hejazi, A.A., et al. (2019). Generation,
transcriptome profiling, and functional validation of cone-rich hu-
man retinal organoids. Proc. Natl. Acad. Sci. U S A 116, 10824–
10833.
Kruczek, K., and Swaroop, A. (2020). Pluripotent stem cell-derived
retinal organoids for disease modeling and development of thera-
pies. Stem Cells 38, 1206–1215.
Kumaran, N., Moore, A.T., Weleber, R.G., and Michaelides, M.
(2017). Leber congenital amaurosis/early-onset severe retinal dys-
trophy: clinical features, molecular genetics and therapeutic inter-
ventions. Br. J. Ophthalmol. 101, 1147–1154.
Lane, A., Jovanovic, K., Shortall, C., Ottaviani, D., Panes, A.B.,
Schwarz, N., Guarascio, R., Hayes, M.J., Palfi, A., Chadderton, N.,
et al. (2020). Modeling and rescue of RP2 retinitis pigmentosa us-
ing iPSC-derived retinal organoids. Stem Cell Rep. 15, 67–79.
Mao, H., James, T., Jr., Schwein, A., Shabashvili, A.E., Hauswirth,
W.W., Gorbatyuk, M.S., and Lewin, A.S. (2011). AAV delivery of
wild-type rhodopsin preserves retinal function in a mouse model
of autosomal dominant retinitis pigmentosa. Hum. Gene Ther.
22, 567–575.
Mitton, K.P., Swain, P.K., Chen, S., Xu, S., Zack, D.J., and Swaroop,
A. (2000). The leucine zipper of NRL interacts with the CRX home-
odomain. A possible mechanism of transcriptional synergy in
rhodopsin regulation. J. Biol. Chem. 275, 29794–29799.
Nichols, L.L., 2nd, Alur, R.P., Boobalan, E., Sergeev, Y.V., Caruso,
R.C., Stone, E.M., Swaroop, A., Johnson, M.A., and Brooks, B.P.
(2010). Two novel CRXmutant proteins causing autosomal domi-
nant Leber congenital amaurosis interact differently with NRL.
Hum. Mutat. 31, E1472–E1483.
Phillips, M.J., Perez, E.T., Martin, J.M., Reshel, S.T., Wallace, K.A.,
Capowski, E.E., Singh, R., Wright, L.S., Clark, E.M., Barney, P.M.,
et al. (2014). Modeling human retinal development with patient-
specific induced pluripotent stem cells reveals multiple roles for vi-
sual system homeobox 2. Stem Cells 32, 1480–1492.
Rivolta, C., Berson, E.L., and Dryja, T.P. (2001). Dominant Leber
congenital amaurosis, cone-rod degeneration, and retinitis pig-mentosa caused by mutant versions of the transcription factor
CRX. Hum. Mutat. 18, 488–498.
Roger, J.E., Hiriyanna, A., Gotoh, N., Hao, H., Cheng, D.F., Ratnap-
riya, R., Kautzmann, M.A., Chang, B., and Swaroop, A. (2014).
OTX2 loss causes rod differentiation defect in CRX-associated
congenital blindness. J. Clin. Invest. 124, 631–643.
Shimada, H., Lu, Q., Insinna-Kettenhofen, C., Nagashima, K., En-
glish, M.A., Semler, E.M., Mahgerefteh, J., Cideciyan, A.V., Li, T.,
Brooks, B.P., et al. (2017). In vitro modeling using ciliopathy-pa-
tient-derived cells reveals distinct cilia dysfunctions caused by
CEP290 mutations. Cell Rep. 20, 384–396.
Swaroop, A., Wang, Q.L., Wu,W., Cook, J., Coats, C., Xu, S., Chen,
S., Zack, D.J., and Sieving, P.A. (1999). Leber congenital amaurosis
caused by a homozygous mutation (R90W) in the homeodomain
of the retinal transcription factor CRX: direct evidence for the
involvement of CRX in the development of photoreceptor func-
tion. Hum. Mol. Genet. 8, 299–305.
Tran, N.M., Zhang, A., Zhang, X., Huecker, J.B., Hennig, A.K., and
Chen, S. (2014). Mechanistically distinct mouse models for CRX-
associated retinopathy. PLoS Genet. 10, e1004111.
Veleri, S., Lazar, C.H., Chang, B., Sieving, P.A., Banin, E., and Swar-
oop, A. (2015). Biology and therapy of inherited retinal degenera-
tive disease: insights from mouse models. Dis. Model. Mech. 8,
109–129.
Watanabe, S., Sanuki, R., Ueno, S., Koyasu, T., Hasegawa, T., and
Furukawa, T. (2013). Tropisms of AAV for subretinal delivery to
the neonatal mouse retina and its application for in vivo rescue
of developmental photoreceptor disorders. PLoS One 8, e54146.
Zhong, X., Gutierrez, C., Xue, T., Hampton, C., Vergara,M.N., Cao,
L.H., Peters, A., Park, T.S., Zambidis, E.T., Meyer, J.S., et al. (2014).
Generation of three-dimensional retinal tissue with functional
photoreceptors from human iPSCs. Nat. Commun. 5, 4047.Stem Cell Reports j Vol. 16 j 252–263 j February 9, 2021 263
